Immunologic mechanisms and treatment of acute coronary syndromes  

作　　者：LIU Ying LIAO Yu-hua CHENG Xiang 

机构地区：[1]Institute of Cardiology, Union Hospital, Tongji Medical College of Huazhong University of Sciences ＆ Technology, Wuhan 430022, China

出　　处：《Chinese Medical Journal》2006年第24期2108-2113,共6页中华医学杂志（英文版）

基　　金：ThisworkwassupportedbyagrantfromNationalNaturalScienceFoundationofChina(No.30600234,30370574).

摘　　要：Acute coronary syndromes （ACS） consist of unstable angina pectoris, non-ST segment elevation myocardial infarction and ST segment elevation myocardial infarction. The pathogenic mechanism of ACS is most often based on thrombosis secondary to plaque rupture in atherosclerosis （AS）. Recent studies indicate that immune and inflammatory responses are associated with the plaque instability in AS.1 Here we review molecular and cellular immunologic processes linked to initiation and progression of ACS and discuss potential applications of immunosuppressant therapy and the possible beneficial immune effects of some cardiovascular medicines used commonly in ACS.Acute coronary syndromes （ACS） consist of unstable angina pectoris, non-ST segment elevation myocardial infarction and ST segment elevation myocardial infarction. The pathogenic mechanism of ACS is most often based on thrombosis secondary to plaque rupture in atherosclerosis （AS）. Recent studies indicate that immune and inflammatory responses are associated with the plaque instability in AS.1 Here we review molecular and cellular immunologic processes linked to initiation and progression of ACS and discuss potential applications of immunosuppressant therapy and the possible beneficial immune effects of some cardiovascular medicines used commonly in ACS.

关 键 词：acute coronary syndrome IMMUNITY STENTS GLUCOCORTICOSTEROIDS RAPAMYCIN 

分 类 号：R541.4[医药卫生—心血管疾病]